Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.
Bioavailability refers to the extent and rate at which the active ingredient of a drug or nutrient is absorbed into the circulation and becomes available at the site of action within the body.
Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.
Regeneron Pharmaceuticals, Inc. has declared the receipt of Complete Response Letters from the U.S. Food and Drug Administration concerning their submitted Biologics License Application for the drug odronextamab.